This interaction not only underscores the importance of PDE4D in HCC progression but also suggests that targeting the PDE4D-YAP axis with roflumilast could be a viable therapeutic strategy for improving patient outcomes [37]. This evidence concerns the gene PDE4D and hepatocellular carcinoma.